Illumina buys Fluent Biosciences, adding single-cell analysis tech

Illumina has bought Fluent Biosciences to add single-cell analysis technology to its portfolio, the company said Tuesday.

Fluent’s technology is designed to generate large single-cell libraries, at a relatively low cost, while removing the need for complex, expensive instrumentation and microfluidic consumables, Illumina said in the announcement.